Expresión y amplificación del gen HER2 en el cáncer gástrico avanzado

Roa, Iván; Slater, Jeannie; Carvajal, Daniel; Schalper, Kurt A.; Toro, Gonzalo de; Ares, Raúl; Game, Anakaren; León, Jorge; Aretxabala, Xabier de

doi:10.4067/s0034-98872013001100007

Cited by 3 publications

(5 citation statements)

References 49 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Chile, where gastric cancer is a highly prevalent malignancy, HER 2 overexpression has been reported in the 11.9% of the patients. These findings have been reported mainly in the intestinal variety of adenocarcinoma but not in diffuse subtype patients [31].…”

Section: Introductionmentioning

confidence: 78%

HER-2 Overexpression in Gastric and Gastroaesophageal Cancer: A Different Disease among Gastric Adenocarcinoma Subtypes

Caglevic¹

2018

ARGH

View full text Add to dashboard Cite

Gastric cancer and gastroesophageal junction adenocarcinoma is a common malignancy worldwide, in particular in Japan and in the Pacific coast of Latin America. Unless early diagnosis is performed, this disease carries a bad prognosis with a high mortality rate regardless of the use of standard treatments. A subgroup of this patients, probably close to a 20 percent, carry HER 2 mutations that result in HER 2 overepression. Targeted treatment to block HER 2 in the first line of treatment in the metastatic setting has resulted in positive outcomes when adding trastuzumab to standard chemotherapy, nonetheless no other HER 2 targeted treatments have reported benefit in this malignancy. Clinical trials are currently ongoing to evaluate the benefit of HER 2 blockade as perioperative treatment for patients that overexpress HER 2.

show abstract

Section: Introductionmentioning

confidence: 78%

HER-2 Overexpression in Gastric and Gastroaesophageal Cancer: A Different Disease among Gastric Adenocarcinoma Subtypes

Caglevic¹

2018

ARGH

View full text Add to dashboard Cite

show abstract

“…Molecular targets are being tested in different populations in LA; for example, HER2 positivity in intestinal GC was 12% in Peru [37] and 16.4% in Chile [38]. These percentages are lower than the previously reported 24% in the validation study by Hoffman et al [39], which raises the biological differences in different regions.…”

Section: New Molecular Targeted Drugs In Advanced Gastric Cancermentioning

confidence: 98%

Role of Chemotherapy in Advanced Gastric Cancer: Review from a Latin American Perspective

Garrido¹,

Jiménez‐Fonseca²,

Solis³

et al. 2016

JCT

View full text Add to dashboard Cite

Gastric cancer (GC) is the fourth most common neoplasm and the second leading cause of cancer-related death worldwide. In Latin America (LA), the burden of this disease is higher and is the leading cause of cancer death in some countries. Chemotherapy is the standard treatment for advanced-stage GC. However, the best regimen for specific populations, such as LA, is as yet unknown. Cisplatin and fluoropyrimidine continue to be the standard of care in light of the findings of phase III studies, while docetaxel, cisplatin, and 5-fluorouracil (5-FU) are alternatives for patients with suitable overall health. Oxaliplatin or irinotecan with fluoropyrimidine can also be used in elderly patients who are not candidates for cisplatin, or have a limited performance status. This review examines studies conducted in LA. Patients from LA are under-represented in multicenter trials of chemotherapy and targeted therapies. The major challenges currently lie in implementing strategies in which patients are selected on the basis of regional, racial or molecular characteristics, to consider the molecular subtype of GC for enrolment, and in selecting patients according to prognostic factors to optimize the benefits of chemotherapy.

show abstract

“…Human epidermal growth factor receptor 2 (HER2), also known as avian erythroblastosis oncogene B 2 (ErbB2), is a cell surface receptor tyrosine kinase that belongs to the HER family (HER1-4) and is involved in cell proliferation, survival, angiogenesis, and migration [6]. There are many reports on molecular abnormalities in a variety of human cancers such as prostate, breast, bladder, and gastric cancers [7][8][9][10][11][12][13][14][15][16]. Under normal circumstances, a cell has two copies of HER2; however, in human cancers, this gene is amplified to more than two copies, a phenomenon known as HER2 copy number gain (CNG) [9,10,[12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…There are many reports on molecular abnormalities in a variety of human cancers such as prostate, breast, bladder, and gastric cancers [7][8][9][10][11][12][13][14][15][16]. Under normal circumstances, a cell has two copies of HER2; however, in human cancers, this gene is amplified to more than two copies, a phenomenon known as HER2 copy number gain (CNG) [9,10,[12][13][14]. HER2 CNG is caused by gene amplification and/or polysomy, and leads to HER2 protein overexpression [9,[12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…Under normal circumstances, a cell has two copies of HER2; however, in human cancers, this gene is amplified to more than two copies, a phenomenon known as HER2 copy number gain (CNG) [9,10,[12][13][14]. HER2 CNG is caused by gene amplification and/or polysomy, and leads to HER2 protein overexpression [9,[12][13][14]. Human patients with HER2-overexpressing cancers show poor prognosis [7,8,11,15,16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human epidermal growth factor receptor 2 is overexpressed in canine prostate carcinoma

Sakai

Shinohara

Kaji

et al. 2021

Translational and Regulatory Sciences

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) is a cell surface receptor tyrosine kinase that belongs to the HER family. HER2 overexpression in human prostate cancer has been frequently observed; however, there are no reports on HER2 expression in canine prostate carcinoma (PC). The purpose of this study was to investigate HER2 expression and the underlying molecular mechanisms in canine PC. Twenty-one formalin-fixed paraffinembedded canine prostate gland tissues (13 carcinomas and 8 normal controls) were analyzed for HER2 expression using immunohistochemistry. Using a digital polymerase chain reaction assay, the HER2 copy number in 8 PC and 6 normal prostate gland tissues was determined. HER2 overexpression occurred in 8/13 (61.5%) PC cases, but not in the normal controls. There were no significant associations between HER2 overexpression and clinical characteristics of the PC cases, such as age, neuter status, lymph node involvement, distant metastasis, and overall survival. HER2 copy number gain (CNG) was detected in 3/8 (37.5%) PC cases, but not in the normal controls. All PC cases with HER2 CNG exhibited HER2 overexpression, suggesting that HER2 CNG may lead to HER2 overexpression. These findings provide new insights into the molecular pathogenesis of canine PC; these may be therapeutically relevant. Dogs with PC would be useful as a preclinical large animal model for the development of new therapy for HER2overexpressing prostate cancer in humans. Key words: prostate carcinoma, human epidermal growth factor receptor 2, protein overexpression, copy number aberration, dog highlights • HER2 overexpression was observed in 61.5% of canine PC cases, suggesting that HER2 can be a therapeutic target in canine PC. • Since all canine PC cases with HER2 CNG exhibited HER2 overexpression, HER2 CNG may be one of the mechanisms underlying HER2 overexpression. • Dogs with HER2-overexpressing PC may be a novel research model for HER2-overexpressing prostate cancer in humans.

show abstract

Expresión y amplificación del gen HER2 en el cáncer gástrico avanzado

Cited by 3 publications

References 49 publications

HER-2 Overexpression in Gastric and Gastroaesophageal Cancer: A Different Disease among Gastric Adenocarcinoma Subtypes

HER-2 Overexpression in Gastric and Gastroaesophageal Cancer: A Different Disease among Gastric Adenocarcinoma Subtypes

Role of Chemotherapy in Advanced Gastric Cancer: Review from a Latin American Perspective

Human epidermal growth factor receptor 2 is overexpressed in canine prostate carcinoma

Contact Info

Product

Resources

About